标题
Neutralizing antibody titres in SARS-CoV-2 infections
作者
关键词
-
出版物
Nature Communications
Volume 12, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-01-04
DOI
10.1038/s41467-020-20247-4
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility
- (2020) Jasper Fuk-Woo Chan et al. CLINICAL INFECTIOUS DISEASES
- Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020
- (2020) Ranawaka APM Perera et al. Eurosurveillance
- Human neutralizing antibodies elicited by SARS-CoV-2 infection
- (2020) Bin Ju et al. NATURE
- SARS-CoV-2 infection protects against rechallenge in rhesus macaques
- (2020) Abishek Chandrashekar et al. SCIENCE
- DNA vaccine protection against SARS-CoV-2 in rhesus macaques
- (2020) Jingyou Yu et al. SCIENCE
- SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls
- (2020) Nina Le Bert et al. NATURE
- Convergent antibody responses to SARS-CoV-2 in convalescent individuals
- (2020) Davide F. Robbiani et al. NATURE
- Potently neutralizing and protective human antibodies against SARS-CoV-2
- (2020) Seth J. Zost et al. NATURE
- Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections
- (2020) Quan-Xin Long et al. NATURE MEDICINE
- Coronavirus Disease 2019 (COVID-19) Re-infection by a Phylogenetically Distinct Severe Acute Respiratory Syndrome Coronavirus 2 Strain Confirmed by Whole Genome Sequencing
- (2020) Kelvin Kai-Wang To et al. CLINICAL INFECTIOUS DISEASES
- Kinetics of viral load and antibody response in relation to COVID-19 severity
- (2020) Yanqun Wang et al. JOURNAL OF CLINICAL INVESTIGATION
- Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate
- (2020) Amin Addetia et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Seasonal coronavirus protective immunity is short-lasting
- (2020) Arthur W. D. Edridge et al. NATURE MEDICINE
- Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans
- (2020) Jeffrey Seow et al. Nature Microbiology
- HAI and NAI titer correlates of inactivated and live attenuated influenza vaccine efficacy
- (2019) Peter B Gilbert et al. BMC INFECTIOUS DISEASES
- Distinguishing Causation from Correlation in the Use of Correlates of Protection to Evaluate and Develop Influenza Vaccines
- (2019) Wey Wen Lim et al. AMERICAN JOURNAL OF EPIDEMIOLOGY
- The Hurdles From Bench to Bedside in the Realization and Implementation of a Universal Influenza Vaccine
- (2018) Sophie A. Valkenburg et al. Frontiers in Immunology
- Influenza hemagglutination-inhibition antibody titer as a mediator of vaccine-induced protection for influenza B
- (2018) Benjamin J Cowling et al. CLINICAL INFECTIOUS DISEASES
- Impact of age and vaccination history on long-term serological responses after symptomatic B. pertussis infection, a high dimensional data analysis
- (2017) Inonge van Twillert et al. Scientific Reports
- Longitudinal profiles of immunoglobulin G antibodies against severe acute respiratory syndrome coronavirus components and neutralizing activities in recovered patients
- (2011) Lifeng Liu et al. SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES
- Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients
- (2010) Zhiliang Cao et al. Virology Journal
- Plasma cell development: From B-cell subsets to long-term survival niches
- (2008) Kirsten A. Fairfax et al. SEMINARS IN IMMUNOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now